Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Julie Maria Bøggild Brøsen; Tobias Bomholt; Rikke Borg; Frederik Persson; Ulrik Pedersen-Bjergaard

doi:10.61409/V01240051

Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Julie Maria Bøggild Brøsen, Tobias Bomholt, Rikke Borg, Frederik Persson, Ulrik Pedersen-Bjergaard

Medicinsk Afdeling Roskilde

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

Bidragets oversatte titel	Hyperglycaemia in people with diabetes and chronic kidney disease
Originalsprog	Dansk
Artikelnummer	V01240051
Antal sider	8
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	20
DOI	https://doi.org/10.61409/V01240051
Status	Udgivet - 13 maj 2024

Bibliografisk note

Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

Emneord

Blood Glucose Self-Monitoring
Blood Glucose/metabolism
Diabetes Mellitus, Type 2/complications
Diabetes Mellitus/blood
Diabetic Nephropathies/complications
Glycated Hemoglobin/analysis
Humans
Hyperglycemia/complications
Hypoglycemic Agents/therapeutic use
Renal Insufficiency, Chronic/complications
Risk Factors

Adgang til dokumentet

10.61409/V01240051Licens: CC BY-NC-ND

Citationsformater

@article{3e5fc254532a4d73a495589095a1ab7a,

title = "Hyperglyk{\ae}mi hos personer med diabetes og kronisk nyresygdom",

abstract = "Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.",

keywords = "Blood Glucose Self-Monitoring, Blood Glucose/metabolism, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus/blood, Diabetic Nephropathies/complications, Glycated Hemoglobin/analysis, Humans, Hyperglycemia/complications, Hypoglycemic Agents/therapeutic use, Renal Insufficiency, Chronic/complications, Risk Factors",

author = "Br{\o}sen, {Julie Maria B{\o}ggild} and Tobias Bomholt and Rikke Borg and Frederik Persson and Ulrik Pedersen-Bjergaard",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = may,

day = "13",

doi = "10.61409/V01240051",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "20",

}

TY - JOUR

T1 - Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

AU - Brøsen, Julie Maria Bøggild

AU - Bomholt, Tobias

AU - Borg, Rikke

AU - Persson, Frederik

AU - Pedersen-Bjergaard, Ulrik

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/5/13

Y1 - 2024/5/13

N2 - Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

AB - Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

KW - Blood Glucose Self-Monitoring

KW - Blood Glucose/metabolism

KW - Diabetes Mellitus, Type 2/complications

KW - Diabetes Mellitus/blood

KW - Diabetic Nephropathies/complications

KW - Glycated Hemoglobin/analysis

KW - Humans

KW - Hyperglycemia/complications

KW - Hypoglycemic Agents/therapeutic use

KW - Renal Insufficiency, Chronic/complications

KW - Risk Factors

U2 - 10.61409/V01240051

DO - 10.61409/V01240051

M3 - Review

C2 - 38808757

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 20

M1 - V01240051

ER -